What happened with VEEV today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Pharmaceutical, biotechnology and medical-device companies use Veeva Systems to manage work from clinical trials and regulatory submissions to product quality and sales. Veeva Development Cloud and Veeva Quality Cloud support development and quality operations and together generate slightly more revenue than its commercial offerings. Veeva Commercial Cloud, including Vault CRM, supports sales, marketing and medical affairs, while Veeva Data Cloud supplies data for those activities.
Customers pay subscriptions to access the software and data, which provide most of Veeva’s revenue. They also pay for implementation, configuration, managed services and business consulting. Revenue depends on customers renewing subscriptions, expanding usage and buying additional applications. Nearly all revenue comes from life sciences customers, so their spending and operating needs matter directly to the business.
Veeva uses Amazon Web Services to host its Vault applications and still relies on Salesforce for legacy Veeva CRM while moving customers to Vault CRM. Its Salesforce agreement now bars sales of Salesforce-based applications to new customers, limits expansion at existing customers and ultimately requires those sales to stop. Veeva’s handling of health and personal data also subjects its products to privacy rules that restrict data use, storage and cross-border transfers.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Veeva’s growth hinges on life sciences spending on software and data, with Dassault Systèmes another important competitor as Veeva expands its development applications business.
IQVIA competes with Veeva for life sciences companies’ spending on healthcare data, analytics, and clinical and commercial software. Its sales of prescribing and treatment information and software for clinical and commercial work are worth watching for competition facing Veeva’s data and application businesses.
Salesforce competes for Veeva’s life sciences customers buying software to manage customer relationships, while supplying the platform and hosting that Veeva’s legacy CRM runs on. Watch Salesforce’s wins among large Veeva CRM customers as they decide whether to move to Vault CRM; the legacy Veeva products remain supported through December 31, 2029.
Definitive Healthcare Corp. competes with Veeva for life sciences sales and marketing teams’ spending on healthcare data and analytics subscriptions. Watch its business with biopharmaceutical and medical-device customers, rather than its broader customer base, for the overlap with Veeva’s data offerings.
Oracle competes with Veeva for life sciences companies buying software for development and quality operations. The overlap is with certain Development Cloud and Quality Cloud applications, not Veeva’s entire application range or Oracle’s whole cloud and software business.
Open Text Corp competes with parts of Veeva’s development and quality business by selling companies software to manage documents and other enterprise content. Its content products are the relevant overlap with Veeva Vault, which manages related documents and data together, rather than its broader data-management portfolio.
Fortrea Holdings Inc. shares Veeva’s exposure to pharmaceutical and biotechnology spending on clinical development: Fortrea is paid to run trials, while Veeva sells clinical software, and Fortrea names Veeva as a strategic technology vendor. Fortrea’s Clinical Services revenue offers a view of spending on outsourced clinical development, not software spending itself.
IQVIA Holdings Inc. earningsIQV
IQVIA's report will show demand from life sciences companies for healthcare data and clinical and commercial software, areas where it competes with Veeva for customer budgets.
Watch sales of IQVIA’s healthcare data and related software. Stronger sales would show that life sciences companies are still spending in these areas, but also that IQVIA is a stronger rival for Veeva’s data and application budgets. Weaker sales could ease competitive pressure while signaling that customers are tightening spending. The key is whether the budgets remain and whether IQVIA is winning more of them.
Fortrea Holdings Inc. earningsFTRE
Fortrea runs clinical trials for pharmaceutical and biotechnology companies, so its report will show how much those customers are spending on outsourced clinical development, a backdrop for demand for Veeva’s clinical software.
Watch the change in Fortrea’s Clinical Services revenue. Growth would show that pharmaceutical and biotechnology companies are still paying outside firms to run trials, supporting the activity Veeva’s clinical software serves. A decline would point to weaker outsourced development activity or spending, which could make customers more cautious with software budgets. Fortrea’s revenue measures clinical services, not Veeva software spending itself.
Open Text Corp earningsOTEX
Open Text Corp's report will show demand for enterprise content-management software, which overlaps with Veeva Vault's work of managing documents and related data.
Focus on demand for Open Text Corp’s content-management products, not its entire software business. Stronger demand would show that customers are still paying for tools to manage documents and content, while presenting Vault with a stronger alternative. Weaker demand could mean less competitive pressure, or tighter enterprise software budgets overall. The report speaks to Vault’s content-management market, not whether Veeva customers have switched.
Veeva Systems Inc. earningsThis company
Veeva sells software and data subscriptions to life sciences companies, and this report will show whether those customers are expanding their use, especially of R&D and Quality products.
Compare subscription growth in R&D and Quality Solutions with growth in Commercial Solutions, then set both against the change in subscription and services revenue. Faster R&D and Quality growth with subscription gross margin holding up would show customers paying for more products without weakening the economics of delivery. Slower growth there, or a weaker margin, would point to less customer expansion or greater cost pressure in serving them.
Salesforce, Inc. earningsCRM
Salesforce's report will show demand for its customer-management software, giving context to competition for life sciences companies choosing between Veeva CRM and Vault CRM.
Watch demand for Salesforce’s customer-management software and whether the report discloses adoption or wins among life sciences customers. Strong demand alongside relevant customer progress would signal a stronger pull on Veeva CRM customers and a more direct rival for Vault CRM. Weaker demand would offer less evidence of that competitive pull. Salesforce’s overall results alone cannot show that a specific Veeva customer has switched or how far Veeva’s migrations have progressed.
